We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Diagnostic Assays Evaluated for Vitamin B12 and Folate Deficiency

By LabMedica International staff writers
Posted on 07 Dec 2020
Current guidelines pertaining to diagnosing macrocytic anemia in association with vitamin B12 and folate deficiency recommend that vitamin B12, folate, homocysteine, and methylmalonic acid assays should be assessed concurrently due to their close relationship in metabolism.

Folate is essential for the prevention of a wide spectrum of health issues, including, most notably, megaloblastic anemia and neural tube defects. More...
Vitamin B12 is a cofactor of methionine synthase and L‐methylmalonyl–coenzyme A mutase, and the interaction between folate and vitamin B12 is responsible for the megaloblastic anemia seen in both vitamin deficiencies.

Medical Laboratorians at the Green Cross Laboratories (Yongin, Republic of Korea) retrospectively reviewed the test results from Korean adults who underwent hemoglobin (Hb) testing between September 25, 2017, and June 30, 2019, through the laboratory information system. The laboratory provides clinical specimen analysis services including serum folate, erythrocyte folate, serum homocysteine, and methylmalonic acid (i.e., serum, plasma, random urine, and 24‐hour collected urine) tests; complete blood count findings including Hb; and erythrocyte mean corpuscular volume (MCV) to clinics and hospitals nationwide.

Hb and MCV were analyzed using Sysmex XN 9000 analyzers (Sysmex Corporation, Kobe, Japan). Serum and erythrocyte folate were determined using the Elecsys Folate assay on Cobas 8000 e801 analyzers (Roche Diagnostics, Mannheim, Germany). Serum homocysteine level was determined using the AutoLab Homocysteine assay (IVD‐LAB, Uiwang-si, South Korea) on Roche Diagnostics’ Cobas 8000 c702 analyzers. Methylmalonic acid concentration in serum, plasma, random urine, and 24‐hour collected urine samples were measured using a Clarus 680 gas chromatography‐mass spectrometry analyzers (PerkinElmer, Waltham, MA, USA).

The scientists reported that during the study period, 109,524 Korean adults completed Hb tests. Among them, 14,894 (13.6%) received concurrent erythrocyte MCV tests. Among these 14,894 adults, 265 adults (107 men and 158 women; 1.2%) aged 23.9 to 95.4 years (median: 68.8 years) had macrocytic anemia, showing Hb findings below the lower limit of the reference interval for each sex and gender and MCV results of greater than 102 fL, from among 94 local clinics or hospitals without in‐house clinical laboratories. Among 265 patients with macrocytic anemia, only one woman underwent both serum vitamin B12 (464 pg/mL, reference interval: 197‐771 pg/mL) and folate (3 ng/mL, reference interval: 3.9‐26.8 ng/mL) assays. Separately, one man from a different clinic underwent serum homocysteine testing during the study period (12.0 µmol/L; upper reference limit: 15.4 µmol/L) and his results were within the reference interval.

The authors concluded that their study provided basic information regarding utilization rates of assays in association with vitamin B12 and folate deficiency. Making more data available is expected to improve rates of testing in patients with macrocytic anemia in local clinics and hospitals without in‐house clinical laboratories in Korea. The study was published on November 6, 2020 in the Journal of Clinical Laboratory Analysis.

Related Links:
Green Cross Laboratories
Sysmex Corporation
Roche Diagnostics
IVD‐LAB
PerkinElmer



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Automatic CLIA Analyzer
Shine i6000
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.